Major Companies in Japan Hydroxyzine Market | Insights & Market Overview 2026

Japan Hydroxyzine Market Overview

According to 6Wresearch, the Japan hydroxyzine market is marked for steady expansion, driven by an aging population prone to chronic dermatological conditions and a rising national focus on mental health. Hydroxyzine in Japan is primarily utilized for its dual-action profile suppressing allergic substances at the H1-receptor level and providing sedative effects by modulating the central nervous system.

Furthermore, the industry is shifting toward enhanced patient compliance, with manufacturers switching from traditional tablets to improved oral solutions and syrups to appeal to pediatric and geriatric populations.

Competitive Landscape

The competitive landscape of the Japan hydroxyzine market is defined by the coexistence of originator brands and a robust generic segment fueled by government initiatives that promote cost-effective healthcare. These companies invest in advanced quality control and stable supply chains to meet the Pharmaceuticals and Medical Devices Agency's (PMDA) stringent criteria.

Below is a list of leading players operating in the Japan Hydroxyzine Market:

1. Pfizer Inc.

A global pharmaceutical leader and the original developer of the Atarax brand (hydroxyzine hydrochloride), which remains a foundational treatment for hives and anxiety in Japan.

2. UCB S.A.

A multinational biopharmaceutical company specializing in immunology and neurology; its Japanese subsidiary (UCB Japan) is a key provider of antihistamine therapies.

3. Teva Pharmaceutical Industries Ltd.

The world's largest generic drug manufacturer, operating in Japan through Teva Takeda Pharma, focusing on providing high-quality, cost-effective hydroxyzine equivalents.

4. Viatris Inc.

Formed via the merger of Mylan and Pfizer's Upjohn, Viatris manages an extensive portfolio of established medicines and generics within the Japanese pharmacy network.

5. Sawai Pharmaceutical Co., Ltd.

One of Japan's premier domestic generic manufacturers, critical for delivering affordable hydroxyzine formulations to reduce national healthcare expenditure.

6. Nichi-Iko Pharmaceutical Co., Ltd.

A major Japanese generic player that ensures a steady supply of essential neurological and respiratory treatments to clinics and hospitals nationwide.

7. Meiji Seika Pharma Co., Ltd.

Leverages its heritage in anti-infectives and CNS disorders to supply specialized antihistamine treatments and anti-anxiety medications.

8. Ohara Pharmaceutical Co., Ltd.

Focuses on specialized generics and orphan drugs, offering hydroxyzine options tailored to specific pediatric dosing and clinical requirements.

9. Towa Pharmaceutical Co., Ltd.

A leading domestic generic manufacturer known for its "Raku-sets" drug delivery technology, enhancing the ease of administration for elderly patients.

10. Taiyo Pharma Co., Ltd.

A specialist in the management of "long-listed" (legacy) brands, ensuring high-reliability products remain available in the competitive Japanese market.

11. Alfresa Pharma Corporation

The manufacturing arm of the Alfresa Group, producing a wide range of ethical pharmaceuticals and diagnostic tools for allergic disorders.

12. Kowa Company, Ltd.

A historic, diversified firm that develops and markets various metabolic and allergic disorder treatments for the Japanese domestic market.

13. Mitsubishi Tanabe Pharma Corporation

A research-driven pharmaceutical company focused on immunology and central nervous system disorders with a global reach.

14. Kyowa Kirin Co., Ltd.

An R&D-based life sciences company that contributes to the broader immunology market through innovative therapeutic advancements.

15. Maruishi Pharmaceutical Co., Ltd.

Specializes in perioperative care and anesthetics, providing essential hydroxyzine-related solutions for hospital-based clinical applications.